|
Name |
2-[2-(2-Hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-3-methyl-1,3-thiazolidine-4-carboxylic acid
|
Molecular Formula | C14H16N2O3S2 | |
IUPAC Name* |
2-[2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-3-methyl-1,3-thiazolidine-4-carboxylic acid
|
|
SMILES |
CN1C(CSC1C2CSC(=N2)C3=CC=CC=C3O)C(=O)O
|
|
InChI |
InChI=1S/C14H16N2O3S2/c1-16-10(14(18)19)7-21-13(16)9-6-20-12(15-9)8-4-2-3-5-11(8)17/h2-5,9-10,13,17H,6-7H2,1H3,(H,18,19)
|
|
InChIKey |
NYBZAGXTZXPYND-UHFFFAOYSA-N
|
|
Synonyms |
Pyochelin; 2-(2-o-hydroxyphenyl-2-thiazolin-4-yl)-3-methylthiazolidine-4-carboxylic acid
|
|
CAS | NA | |
PubChem CID | 135583337 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 324.4 | ALogp: | -0.3 |
HBD: | 2 | HBA: | 7 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 124.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 21 | QED Weighted: | 0.889 |
Caco-2 Permeability: | -6.152 | MDCK Permeability: | 0.00000391 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.013 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.004 |
Blood-Brain-Barrier Penetration (BBB): | 0.405 | Plasma Protein Binding (PPB): | 51.42% |
Volume Distribution (VD): | 1.413 | Fu: | 55.16% |
CYP1A2-inhibitor: | 0.223 | CYP1A2-substrate: | 0.173 |
CYP2C19-inhibitor: | 0.038 | CYP2C19-substrate: | 0.306 |
CYP2C9-inhibitor: | 0.045 | CYP2C9-substrate: | 0.609 |
CYP2D6-inhibitor: | 0.059 | CYP2D6-substrate: | 0.27 |
CYP3A4-inhibitor: | 0.009 | CYP3A4-substrate: | 0.097 |
Clearance (CL): | 7.588 | Half-life (T1/2): | 0.791 |
hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.228 |
Drug-inuced Liver Injury (DILI): | 0.971 | AMES Toxicity: | 0.006 |
Rat Oral Acute Toxicity: | 0.033 | Maximum Recommended Daily Dose: | 0.837 |
Skin Sensitization: | 0.117 | Carcinogencity: | 0.346 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.014 |
Respiratory Toxicity: | 0.344 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003518 | 0.494 | D07HBX | 0.323 | ||||
ENC003600 | 0.494 | D0F5ZM | 0.278 | ||||
ENC003520 | 0.365 | D04KTZ | 0.266 | ||||
ENC003519 | 0.338 | D0K0KH | 0.263 | ||||
ENC001378 | 0.338 | D0J5KF | 0.263 | ||||
ENC000409 | 0.309 | D0Z5EM | 0.263 | ||||
ENC001547 | 0.296 | D06VFO | 0.260 | ||||
ENC000104 | 0.290 | D0G7FJ | 0.258 | ||||
ENC004704 | 0.288 | D0R1BD | 0.258 | ||||
ENC000108 | 0.284 | D0D9JW | 0.256 |